Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: COPD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg BID compared with placebo on COPD symptoms in a symptomatic patients population with moderate COPD and chronic bronchitis, and particularly assess the effects in cough by using specific tools to assess the occurrence and impact of this relevant COPD symptom.

Detailed description:

Arms:
arm 1: Aclidinium Bromide 400 μg twice daily by inhalation arm 2: placebo twice daily by inhalation

Interventions: intervention 1: Aclidinium Bromide intervention 2: Placebo
Intervention descriptions: intervention 1: Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler intervention 2: Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler

Protocol document: